Collectively, these results suggest that DDB2 and XPC play key roles in KRAS mutation-driven platinum resistance in NSCLC cells and that KRAS mutations confer drug resistance by enhancing NER activity. This evidence concerns the gene KRAS and non-small cell lung carcinoma.